Refractory Lymphomas Terminated Phase 1 / 2 Trials for Doxorubicin (DB00997)

Also known as: Refractory Lymphoma

IndicationStatusPhase
DBCOND0042145 (Refractory Lymphomas)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00785798Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory LymphomasTreatment